Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Earnings grew barely 14% last quarter -- and over the past year, the stock has lost roughly half its value. The board cited these "recent market challenges Novo Nordisk has been facing ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most ...

Weight loss drugmaker Novo Nordisk (NVO ... was made in light of the company’s recent market challenges and the performance of its stock since mid-2024. Jørgensen has agreed to serve as ...

"Considering the recent market challenges, the share price decline ... Read more about Novo Nordisk's stock moves and today's market action. After years of being known for its insulin and diabetes ...